. 2023 Jan 12;10(2):307–327. doi: 10.1007/s40744-022-00522-0

Table 3.

Summary of base-case ITC results (CZP vs. comparator bDMARDs at 12–16 weeks)

	ADA	ETN	GOL	IXE Q2W	IXE Q4W	SEC NL	SEC LD
ASAS20^a	1.48 (0.72, 3.06)^c	4.78 (1.89, 12.09)	1.96 (0.74, 5.20)	2.82 (1.39, 5.74)^c	3.15 (1.54, 6.43)^c	3.37 (1.88, 6.01)^c	3.56 (2.00, 6.36)^c
ASAS40^a	2.13 (0.89, 5.13)^c	4.90 (1.65, 14.56)	1.45 (0.55, 3.84)	2.69 (1.09, 6.61)^c	3.30 (1.33, 8.18)^c	3.76 (1.98, 7.12)^c	3.88 (2.05, 7.35)^c
ASDAS-ID^a	4.59 (0.58, 36.58)^c	10.60 (1.65, 68.26)^c	4.19 (1.09, 16.14)^c	3.96 (1.05, 14.91)^c	5.10 (1.34, 19.42)^c	3.80 (0.97, 14.86)	4.08 (1.04, 15.99)
ASDAS-MI^a	1.81 (0.21, 15.46)^c	NA	NA	NA	NA	2.00 (0.83, 4.82)	2.07 (0.86, 5.00)
BASDAI^b	−0.94 (−1.53,− 0.34)^c	−1.59 (−2.63, −0.55)	−0.16 (−1.12, 0.80)	−1.09 (−1.85, −0.34)^c	−1.43 (−2.19, −0.68)^c	−0.84 (−1.81, 0.13)	−0.92 (−1.89, 0.05)
BASFI^b	−1.27 (−1.99, −0.55)^c	−1.67 (−2.53, −0.81)	−0.17 (−1.09, 0.75)	−1.02 (−1.86, −0.19)^c	−1.29 (−2.13, −0.46)^c	−1.53 (−2.46, −0.60)	−1.38 (−2.31, −0.45)
Total Spinal Pain^b	−0.98 (−1.66, −0.29)^c	−1.21 (−2.27, −0.15)^c	−0.08 (−0.95, 0.79)^c	−1.28 (−2.10, −0.46)^c	−1.52 (−2.35, −0.69)^c	NA	NA

Bold = estimate significantly favors CZP

ADA adalimumab, ASAS20 Assessment in SpondyloArthritis International Society 20% Response Criteria, ASAS40 Assessment in SpondyloArthritis International Society 40% Response Criteria, ASDAS-ID Ankylosing Spondylitis Disease Activity Score-Inactive Disease, ASDAS-MI Ankylosing Spondylitis Disease Activity Score-Major Improvement, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, ETN etanercept, GOL golimumab, IXE ixekizumab, LD loading dose, NA not applicable, NL non-loading dose, Q2W every other week, Q4W every four weeks, SEC secukinumab

^aResults are presented as odds ratios (95% confidence interval)

^bResults are presented as mean differences (95% confidence interval)

^cRandom-effects model was used